Xenetic Biosciences, Inc. (NASDAQ:XBIO) Sees Significant Increase in Short Interest

Xenetic Biosciences, Inc. (NASDAQ:XBIO) was the target of a large growth in short interest during the month of June. As of June 30th, there was short interest totaling 23,589 shares, a growth of 158.0% from the June 15th total of 9,143 shares. Approximately 1.1% of the company’s stock are sold short. Based on an average daily trading volume, of 19,757 shares, the days-to-cover ratio is presently 1.2 days.

Hedge Funds Weigh In On Xenetic Biosciences

A hedge fund recently bought a new position in Xenetic Biosciences stock. DRW Securities LLC bought a new stake in shares of Xenetic Biosciences, Inc. (NASDAQ:XBIO) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 13,824 shares of the company’s stock, valued at approximately $30,000. DRW Securities LLC owned approximately 0.60% of Xenetic Biosciences at the end of the most recent reporting period. Institutional investors own 15.12% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xenetic Biosciences in a research note on Monday, April 20th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has an average rating of “Sell”.

Xenetic Biosciences Trading Down 3.3%

Shares of XBIO opened at $2.90 on Thursday. The firm’s 50-day moving average is $3.00 and its two-hundred day moving average is $2.76. Xenetic Biosciences has a twelve month low of $1.90 and a twelve month high of $13.93. The firm has a market capitalization of $6.64 million, a P/E ratio of -2.42 and a beta of 2.19.

Xenetic Biosciences (NASDAQ:XBIO) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.20) earnings per share (EPS) for the quarter. The company had revenue of $0.81 million for the quarter. Xenetic Biosciences had a negative net margin of 70.03% and a negative return on equity of 39.28%.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.

At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.